X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
mesna (36) 36
animals (30) 30
humans (30) 30
male (30) 30
oncology (28) 28
rats (22) 22
2-mercaptoethane sulfonate (21) 21
female (21) 21
index medicus (20) 20
2-mercaptoethane sulfonate mesna (19) 19
mesna - administration & dosage (18) 18
ifosfamide (17) 17
cyclophosphamide (15) 15
pharmacology & pharmacy (15) 15
adult (14) 14
mesna - pharmacology (13) 13
mesna - therapeutic use (13) 13
rats, wistar (12) 12
chemotherapy (11) 11
prevention (11) 11
sulfonate (11) 11
surgery (11) 11
toxicity (11) 11
ifosfamide - adverse effects (10) 10
middle aged (10) 10
cancer (9) 9
glutathione (9) 9
mesna - pharmacokinetics (9) 9
pharmacokinetics (9) 9
urine (9) 9
administration, oral (8) 8
mesna - analogs & derivatives (8) 8
mice (8) 8
oxidative stress (8) 8
protective agents - therapeutic use (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
biochemistry & molecular biology (7) 7
chemistry, analytical (7) 7
cystitis - chemically induced (7) 7
cystitis - prevention & control (7) 7
glutathione - metabolism (7) 7
ischemia/reperfusion injury (7) 7
mesna - metabolism (7) 7
rat (7) 7
sodium 2-mercaptoethane sulfonate (7) 7
time factors (7) 7
urotoxicity (7) 7
aged (6) 6
antioxidants (6) 6
bladder (6) 6
child (6) 6
cystitis (6) 6
efficacy (6) 6
hemorrhage - chemically induced (6) 6
hemorrhage - prevention & control (6) 6
hemorrhagic cystitis (6) 6
high-dose ifosfamide (6) 6
ifosfamide - administration & dosage (6) 6
medicine & public health (6) 6
oxidative stress - drug effects (6) 6
performance liquid-chromatography (6) 6
plasma (6) 6
protective agents - administration & dosage (6) 6
sodium (6) 6
thiols (6) 6
adolescent (5) 5
antineoplastic agents, alkylating - adverse effects (5) 5
apoptosis (5) 5
cell lung-cancer (5) 5
dimesna (5) 5
drug interactions (5) 5
lipid-peroxidation (5) 5
mesna - adverse effects (5) 5
nitric oxide (5) 5
phase-ii trial (5) 5
protective agents - pharmacology (5) 5
cross-over studies (4) 4
damage (4) 4
dose-response relationship, drug (4) 4
drug administration schedule (4) 4
electrochemical detection (4) 4
enzymes (4) 4
gastroenterology & hepatology (4) 4
ifosfamide - pharmacokinetics (4) 4
induced hemorrhagic cystitis (4) 4
infusions, intravenous (4) 4
injections, intravenous (4) 4
ischemia-reperfusion (4) 4
kidney (4) 4
liver (4) 4
mesna - analysis (4) 4
mesna - blood (4) 4
mesna - chemistry (4) 4
metabolism (4) 4
n-acetylcysteine (4) 4
neoplasms - drug therapy (4) 4
nitric-oxide synthase (4) 4
oxidation-reduction (4) 4
oxidoreductases - chemistry (4) 4
oxidoreductases - metabolism (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 04/2015, Volume 10, Issue 4, pp. e0124988 - e0124988
Journal Article
International Journal of Experimental Pathology, ISSN 0959-9673, 12/2015, Volume 96, Issue 6, pp. 433 - 443
Journal Article
International Journal of Pharmacology, ISSN 1811-7775, 10/2017, Volume 13, Issue 8, pp. 1038 - 1046
Background and Objective: An ischemia-reperfusion (I/R) injury of small intestine is a serious and common condition that is a result of the blockage of the... 
Ischemia-reperfusion | Arginase | Mesna | Synthase | Intestine | Nitric oxide | mesna | nitric oxide | ISCHEMIA/REPERFUSION INJURY | OXIDATIVE STRESS | intestine | ARTERY-OCCLUSION SHOCK | ischemia-reperfusion | 2-MERCAPTOETHANE SULFONATE | DAMAGE | INFLAMMATORY-BOWEL-DISEASE | synthase | LIVER | INOS EXPRESSIONS | PHARMACOLOGY & PHARMACY | KIDNEY
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 02/2008, Volume 23, Issue 2, pp. 328 - 335
Background and Aim:  Mesna (2‐mercaptoethane‐sulfonate) has been shown to attenuate oxidative injury induced by ischemia reperfusion (I/R) in the kidneys, the... 
mesna | intestine | nuclear factor‐κB | oxidative stress | Oxidative stress | Mesna | Nuclear factor-κB | Intestine | APOPTOSIS | ISCHEMIA/REPERFUSION INJURY | ANTIOXIDATIVE AGENTS | EFFICACY | QUANTITATION | RATS | nuclear factor-kappa B | PROTEIN-DYE BINDING | 2-MERCAPTOETHANE SULFONATE | MUCOSA | MICROGRAM QUANTITIES | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal of Chromatographic Science, ISSN 0021-9665, 05/2015, Volume 53, Issue 5, pp. 742 - 748
A rapid and simple stability-indicating liquid chromatographic method was developed and validated for analysis of mesna in the presence of its degradation... 
PERFORMANCE LIQUID-CHROMATOGRAPHY | CHEMISTRY, ANALYTICAL | SODIUM 2-MERCAPTOETHANE SULFONATE | ULTRAVIOLET DETECTION | BIOCHEMICAL RESEARCH METHODS
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 1993, Volume 11, Issue 1, pp. 173 - 190
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 2005, Volume 509, Issue 1, pp. 61 - 70
Lung fibrosis is a common side effect of the chemotherapeutic agent, bleomycin. Current evidence suggests that reactive oxygen species may play a key role in... 
Mesna | Lung fibrosis | Bleomycin | bleomycin | mesna | NITRIC-OXIDE SYNTHASE | TOXICITY | lung fibrosis | ANGIOTENSIN-CONVERTING ENZYME | 2-MERCAPTOETHANE SULFONATE | IFOSFAMIDE | REACTIVE OXYGEN | INDUCED PULMONARY-FIBROSIS | GLUTATHIONE | PHARMACOLOGY & PHARMACY | MICE | PLATELET-ACTIVATING-FACTOR | Tumor Necrosis Factor-alpha - metabolism | Nitric Oxide Synthase - chemistry | Bleomycin - antagonists & inhibitors | Rats, Wistar | Glutathione - metabolism | Lung - chemistry | Hydroxyproline - adverse effects | Male | Peptidyl-Dipeptidase A - drug effects | Weight Loss - drug effects | Mesna - adverse effects | Glutathione - drug effects | Time Factors | Peptidyl-Dipeptidase A - metabolism | Lung - ultrastructure | Weight Gain - drug effects | Platelet Activating Factor - drug effects | Hydroxyproline - chemistry | Mesna - administration & dosage | Peroxidase - drug effects | Drug Administration Schedule | Hydroxyproline - metabolism | Injections, Intraperitoneal | Mesna - pharmacokinetics | Rats | Glutathione - antagonists & inhibitors | Bleomycin - administration & dosage | Bleomycin - adverse effects | Platelet Activating Factor - metabolism | Animals | Tumor Necrosis Factor-alpha - drug effects | Lung - drug effects | Pulmonary Fibrosis - physiopathology | Pulmonary Fibrosis - chemically induced | Nitric Oxide Synthase - metabolism | Pulmonary Fibrosis - drug therapy | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Drug Screening Assays, Antitumor | Peroxidase - metabolism | Hydroxyproline | Respiratory agents | Peptide hormones | Platelet activating factor | Chemotherapy | Collagen | Nitric oxide | Fibrosis | Angiotensin | Angiotensin converting enzyme | Cancer | Glutathione
Journal Article
Acta Neurochirurgica, ISSN 0001-6268, 1/2013, Volume 155, Issue 1, pp. 141 - 149
Journal Article